Similar articles for PMID: 24692676

Year	Number of Results
1973	1
2002	1
2006	2
2010	6
2011	17
2012	26
2013	31
2014	52
2015	67
2016	51
2017	34
2018	21
2019	20
2020	17
2021	18
2022	8
2023	2
2024	0

1

New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.

Azijli K, Stelloo E, Peters GJ, VAN DEN Eertwegh AJ. Azijli K, et al. Anticancer Res. 2014 Apr;34(4):1493-505. Anticancer Res. 2014. PMID: 24692676 Review.

2

Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".

Jarkowski A 3rd, Norris L, Trinh VA. Jarkowski A 3rd, et al. Ann Pharmacother. 2014 Nov;48(11):1456-68. doi: 10.1177/1060028014544165. Epub 2014 Jul 23. Ann Pharmacother. 2014. PMID: 25056920 Review.

3

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

Olszanski AJ. Olszanski AJ. J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. doi: 10.18553/jmcp.2014.20.4.346. J Manag Care Spec Pharm. 2014. PMID: 24684639 Free PMC article. Review.

4

Gaining momentum: New options and opportunities for the treatment of advanced melanoma.

Michielin O, Hoeller C. Michielin O, et al. Cancer Treat Rev. 2015 Sep;41(8):660-70. doi: 10.1016/j.ctrv.2015.05.012. Epub 2015 Jun 4. Cancer Treat Rev. 2015. PMID: 26096079 Review.

5

Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?

Gibney GT, Atkins MB. Gibney GT, et al. Clin Adv Hematol Oncol. 2015 Jul;13(7):451-8. Clin Adv Hematol Oncol. 2015. PMID: 26353041 Review.

6

BRAF, a target in melanoma: implications for solid tumor drug development.

Flaherty KT, McArthur G. Flaherty KT, et al. Cancer. 2010 Nov 1;116(21):4902-13. doi: 10.1002/cncr.25261. Cancer. 2010. PMID: 20629085 Free article. Review.

7

Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.

Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, Meier F. Kuske M, et al. Pharmacol Res. 2018 Oct;136:151-159. doi: 10.1016/j.phrs.2018.08.019. Epub 2018 Aug 23. Pharmacol Res. 2018. PMID: 30145328 Free article. Review.

8

The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.

Vanella V, Festino L, Trojaniello C, Vitale MG, Sorrentino A, Paone M, Ascierto PA. Vanella V, et al. Curr Oncol Rep. 2019 Jul 29;21(9):76. doi: 10.1007/s11912-019-0827-x. Curr Oncol Rep. 2019. PMID: 31359162 Review.

9

Vemurafenib for the treatment of melanoma.

Jordan EJ, Kelly CM. Jordan EJ, et al. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. Expert Opin Pharmacother. 2012. PMID: 23094782 Review.

10

Trametinib in metastatic melanoma.

Chopra N, Nathan PD. Chopra N, et al. Expert Rev Anticancer Ther. 2015;15(7):749-60. doi: 10.1586/14737140.2015.1060127. Expert Rev Anticancer Ther. 2015. PMID: 26107021 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

343 results

Results by year